Exanta Committee Review Reflects "Regulatory" Vs. "Clinical" Medicine – AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca tells investors it cannot determine what its next step will be in the U.S. until it hears from FDA by the Oct. 23 user fee date. CEO McKillop says "we can't be optimistic about the outcome of discussions with the FDA."
You may also be interested in...
AstraZeneca’s Exanta “Not Approvable” At FDA
Review decision comes two weeks ahead of the anticoagulant’s user fee date and follows CEO McKillop’s comments to investors that “we can’t be optimistic about the outcome of discussions with the FDA.”
AstraZeneca’s Exanta “Not Approvable” At FDA
Review decision comes two weeks ahead of the anticoagulant’s user fee date and follows CEO McKillop’s comments to investors that “we can’t be optimistic about the outcome of discussions with the FDA.”
AstraZeneca's Galida Filing Delayed Until 2007 Due To PPAR Safety Concerns
Long-term patient follow-up is extended to two years in light of regulatory concerns about PPAR class safety, firm tells analysts. News is setback for AstraZeneca's near-term cardiovascular pipeline and a boost for Bristol/Merck's muraglitazar.